Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
The latest update is out from Hansa Biopharma AB ( (SE:HNSA) ).
Hansa Biopharma announced key executive appointments to bolster its growth and enhance expertise in legal, human resources, and corporate affairs. Brian Gorman, Sandra Frithiof, and Kerstin Falck Lagercrantz join the company in pivotal roles, bringing extensive experience to support Hansa’s strategic initiatives, particularly as it prepares for US pre-commercial activities. These appointments are expected to strengthen Hansa’s operational capabilities and industry positioning, potentially impacting stakeholders positively as the company advances its Phase 3 readouts and BLA submission.
The most recent analyst rating on (SE:HNSA) stock is a Buy with a SEK175.00 price target. To see the full list of analyst forecasts on Hansa Biopharma AB stock, see the SE:HNSA Stock Forecast page.
More about Hansa Biopharma AB
Hansa Biopharma AB is a commercial-stage biopharmaceutical company focused on developing and commercializing innovative treatments for rare immunological conditions. The company leverages its proprietary IgG-cleaving enzyme technology platform to address unmet medical needs in autoimmune diseases, gene therapy, and transplantation. Its portfolio includes imlifidase, an IgG antibody-cleaving enzyme therapy that facilitates kidney transplantation in highly sensitized patients, and HNSA-5487, a next-generation IgG cleaving molecule with redosing potential. Based in Lund, Sweden, Hansa operates in Europe and the U.S. and is listed on Nasdaq Stockholm.
Average Trading Volume: 253,841
Technical Sentiment Signal: Sell
Current Market Cap: SEK2.31B
For an in-depth examination of HNSA stock, go to TipRanks’ Overview page.